Abstract: Polyoxazoline polymers, polymer combinations, and compositions comprising those polymers or combinations of polymers are disclosed. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.

Abstract: The present invention relates to solution electrospun fibers comprising a ingredient in an amorphous form, compositions and their manufacturing process thereof. More specifically, the present invention relates to solution electrospun fibers and a compositions comprising at least one of said fibers, said fiber obtained by solution electrospinning a ingredient with a polymer.

Abstract: The present invention relates to water-soluble or water-dispersible granules that comprise a binder, a filler and an active ingredient. Preferred granules of the invention are obtained by continuous melt granulation of a mixture that comprises 65-70 weight-% active ingredient. 15-25 weight-% filler and 5-15 weight-% binder, based on the total weight of the mixture. Ascorbic acid and edible salts thereof are the preferred active ingredients.

Abstract: The present invention relates to water-soluble or water-dispersible granules that are obtainable by continuous melt granulation. The granules comprise at least one binder, at least one filler and at least one active ingredients. Torque overload may be avoided when using a combination of the herein disclosed filler (e.g. mannitol or an HIMO) and binder (e.g. sorbitol).

Abstract: The present invention relates to water-soluble or water-dispersible granules that are obtainable by continuous melt granulation. In an embodiment, the granules comprise at least one binder, at least one filler and microcapsules that encapsulate fat-soluble active ingredients.

Abstract: Polyoxazoline polymers, polymer combinations, and compositions comprising those polymers or combinations of polymers are disclosed. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.

Abstract: The present invention relates to polyoxazoline polymers, polymer combinations and compositions comprising those polymers or combinations of polymers. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.

Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

Abstract: The present invention relates to polyoxazoline polymers, polymer combinations and compositions comprising those polymers or combinations of polymers. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.

Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

Abstract: The present invention relates to solid pharmaceutical dosage forms suitable for use as drinking water medication. More in particular, the present invention provides solid pharmaceutical dosage forms comprising a pharmaceutically active agent, a non-ionic surfactant having an Hydrophilic Lipophilic Balance (HLB) of at least 8, and a maltodextrin. The present invention also provides the use of such pharmaceutical dosage forms in veterinary medicine, more in particular as drinking water medication; as well as methods for preparing such pharmaceutical dosage forms.

Abstract: The present invention in general relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one active ingredient and at least one dicarboxylic acid. It in particular relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one anthelmintic drug and at least one dicarboxylic acid. The invention further relates to uses, methods for use and methods for manufacturing the pharmaceutical suspension according to this invention.

Abstract: The present invention relates to solid pharmaceutical dosage forms suitable for use as drinking water medication. More in particular, the present invention provides solid pharmaceutical dosage forms comprising a pharmaceutically active agent, a non-ionic surfactant having an Hydrophilic Lipophilic Balance (HLB) of at least 8, and a maltodextrin. The present invention also provides the use of such pharmaceutical dosage forms in veterinary medicine, more in particular as drinking water medication; as well as methods for preparing such pharmaceutical dosage forms.

Abstract: An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and stem cells.

Abstract: An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and stem cells.

Abstract: An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and stem cells.